Our Clinical Research Associates (CRAs) are one of the strongest links in the chain of a clinical study and act as the main line of communication between investigators and our clients. While always ensuring subjects' wellbeing and rights and data reliability, they promote and uphold the image and values of our clients’ company at all times. Their professionalism and enthusiasm is second to none in the market.
We offer our CRAs a comprehensive internal and external training program featuring Standard Operating Procedures (SOPs), Good Clinical Practice (GCP) and regulatory requirements. In addition, they receive project specific training before the start of any projects.
All monitoring activities are conducted according to the international standards of ICH/GCP.
With the support of their Project Manager and Line Manager, our CRAs are accountable for:
- Investigational site identification and qualification
- Collection, review and tracking of essential documents
- Site initiation, ongoing monitoring and closure of investigational sites
- Reporting and tracking of monitoring activities
- In-house site management
Early Stage Clinical Trials / Phase II and III Clinical Trials
Late Phase Clinical Trials / Post Marketing Safety Studies
Product Value and Effectiveness in Real-world
Public Health and Social Science Research
Health News - Africa
- Uganda: Covid-19 Stands in the Way of HIV/Aids Fight
- Seychelles: Health Official Warns of Possible Rise in HIV/Aids Cases in Seychelles During Year of Covid
- Malawi: Malawi Prisons Registers No Covid-19
- Malawi: Malawi Makes Progress in HIV and Aids Fight - Chakwera
- South Africa: Aids Victories Show What We Can Do If We Try
- Ethiopia: HIV/ Aids in Alarming Rate in Addis Ababa - Office
- Africa: South Africa Has the Best HIV Policies, Report Finds
- Africa: A critical HIV situation in Central African Republic - A state of silent crisis
- South Africa: Will Covid-19 Vaccines Bring Life Back to Normal in 2021?
- South Africa: Western Cape Finance and Economic Opportunities Releases Procurement Disclosure Report On Covid-19 Spending